Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow OMEROS CORP

Get SEC filing alerts via email and in your feed for OMEROS CORP

OMER

OMEROS CORP

About OMEROS CORP

Omeros Corporation is a clinical-stage biopharmaceutical company developing small-molecule and protein therapeutics targeting immune-related diseases, including complement-mediated disorders, cancers, and addiction. Its lead programs focus on complement system inhibitors, notably narsoplimab for thrombotic microangiopathies, and zaltenibart for rare blood and kidney diseases. The company owns extensive intellectual property and retains worldwide rights for its innovative biologics and small-molecule drug candidates.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from OMEROS CORP

1
1
OMEROS CORP Omeros Corporation Reports $9.9M in Product Sales and $56.1M Net Income for Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
OMEROS CORP Omeros Corporation Reports $1.5M Net Income from Discontinued Operations and $237.6M Total Revenue for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
OMEROS CORP Omeros Corporation Reports $30.9 Million Net Loss in Q3 2025, Enters Agreement with Novo Nordisk

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
OMEROS CORP Omeros Corporation Reports Improved Net Loss of $25.4 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
OMEROS CORP Omeros Corporation Reports $33.5 Million Net Loss and $1.1 Million Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
OMEROS CORP Omeros Corporation Reports $156.8 Million Net Loss for 2024, Focuses on Product Pipeline

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
OMEROS CORP Omeros Corporation Reports Net Loss, Decreased Cash Reserves, and Strategic Efforts in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments